摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

tert-butyl 7-bromo-2,3-dihydro-1H-imidazo[1,2-b]pyrazole-1-carboxylate | 1776066-29-5

中文名称
——
中文别名
——
英文名称
tert-butyl 7-bromo-2,3-dihydro-1H-imidazo[1,2-b]pyrazole-1-carboxylate
英文别名
tert-butyl 7-bromo-2,3-dihydroimidazo[1,2-b]pyrazole-1-carboxylate
tert-butyl 7-bromo-2,3-dihydro-1H-imidazo[1,2-b]pyrazole-1-carboxylate化学式
CAS
1776066-29-5
化学式
C10H14BrN3O2
mdl
——
分子量
288.144
InChiKey
PKIOSMBETRQYBN-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.7
  • 重原子数:
    16
  • 可旋转键数:
    2
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.6
  • 拓扑面积:
    47.4
  • 氢给体数:
    0
  • 氢受体数:
    3

反应信息

点击查看最新优质反应信息

文献信息

  • ALK5 INHIBITORS
    申请人:THERAVANCE BIOPHARMA R&D IP, LLC
    公开号:US20200188370A1
    公开(公告)日:2020-06-18
    The present disclosure provides inhibitors of activin receptor-like kinase 5 (ALK5). Also disclosed are methods to modulate the activity of ALK5 and methods of treatment of disorders mediated by ALK5.
    本公开提供抑制活性素受体样激酶5(ALK5)的抑制剂。还公开了调节ALK5活性的方法以及治疗由ALK5介导的疾病的方法。
  • TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS
    申请人:Forma Therapeutics, Inc.
    公开号:US20150232445A1
    公开(公告)日:2015-08-20
    The present invention relates to inhibitors of bromo and extra terminal (BET) bromodomains that are useful for the treatment of cancer, inflammatory diseases, diabetes, and obesity, having Formula I: wherein W, X, Y, Z, R 1 , R 2 , R 5 , and R 8 are as described herein.
    本发明涉及抑制和额外末端(BET)域的抑制剂,其可用于治疗癌症、炎症性疾病、糖尿病和肥胖症,其化学式为I:其中W、X、Y、Z、R1、R2、R5和R8如本文所述。
  • Tetrahydroquinoline compositions as BET bromodomain inhibitors
    申请人:Forma Therapeutics, Inc.
    公开号:US09388161B2
    公开(公告)日:2016-07-12
    The present invention relates to inhibitors of bromo and extra terminal (BET) bromodomains that are useful for the treatment of cancer, inflammatory diseases, diabetes, and obesity, having Formula I: wherein W, X, Y, Z, R1, R2, R5, and R8 are as described herein.
    本发明涉及用于治疗癌症、炎症性疾病、糖尿病和肥胖症的和额外末端(BET)抑制剂,具有公式I:其中W、X、Y、Z、R1、R2、R5和R8如本文所述。
  • TETRAHYDROQUINOLINE DERIVATIVES FOR USE AS BET INHIBITORS
    申请人:Forma Therapeutics, Inc.
    公开号:EP3799872A1
    公开(公告)日:2021-04-07
    The present invention relates to inhibitors of bromo and extra terminal (BET) bromodomains that are useful for the treatment of cancer, inflammatory diseases, diabetes, and obesity, having Formula I: wherein W, X, Y, Z, R1, R2, R5, and R8 are as described herein.
    本发明涉及可用于治疗癌症、炎症性疾病、糖尿病和肥胖症的具有式 I 的外末端 (BET) odomains 抑制剂: 其中 W、X、Y、Z、R1、R2、R5 和 R8 如本文所述。
  • Tetrahydroquinoline compositions as bet bromodomain inhibitors
    申请人:FORMA Therapeutics, Inc.
    公开号:US10611750B2
    公开(公告)日:2020-04-07
    The present invention relates to inhibitors of bromo and extra terminal (BET) bromodomains that are useful for the treatment of cancer, inflammatory diseases, diabetes, and obesity, having Formula I: wherein W, X, Y, Z, R1, R2, R5, and R8 are as described herein.
    本发明涉及可用于治疗癌症、炎症性疾病、糖尿病和肥胖症的具有式 I 的外末端 (BET) odomains 抑制剂: 其中 W、X、Y、Z、R1、R2、R5 和 R8 如本文所述。
查看更多